Clinical trials in Brescia – page 25

554 clinical trials in Brescia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Brescia at a glance

554

clinical trials

Research sites2

Quick filters

554 trials in Brescia

Open in trial search

Dermatomyositis+3

Not recruiting

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug

Phase 2 Study of Daxdilimab with Prednisone in Adults with Inadequately Controlled Dermatomyositis or Anti‑Synthetase Inflammatory Myositis

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Daxdilimab
Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Contact Research Centre

Relapsing multiple sclerosis

Not recruiting

Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis

Registered drug

Phase III Study of the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis

Registered drug

Italy

Participants:18–64 years
Substances:Fenebrutinib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Cervix carcinoma+1

Not recruiting

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Exelixis Inc.

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Florbetaben (18F)
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A study testing MK-1167 added to current treatment in patients with mild to moderate Alzheimer's disease dementia

Investigational

A study testing MK-1167 added to current treatment in patients with mild to moderate Alzheimer's disease dementia

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Mk-1167
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:BioNTech SE

Contact Research Centre

Vitiligo

Not recruiting

A Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is

Investigational

A Study Testing Zasocitinib Compared to Placebo in Adults with Nonsegmental Vitiligo to See How Well It Works and How Safe It Is

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Zasocitinib
Sponsor:Takeda Development Center Americas Inc.

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Gsk4527226
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Non-small cell lung cancer stage III

Not recruiting

Study of radiotherapy with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer who have thoracic relapse after PACIFIC treatment

Registered drugNo placebo

Study of radiotherapy with durvalumab and ceralasertib in patients with stage III non-small cell lung cancer who have thoracic relapse after PACIFIC treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ceralasertib
Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Brescia

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on metastatic colorectal cancer, chronic myeloid leukemia, and renal cell carcinoma. Studies evaluate novel combination therapies and treatment strategies for advanced cancer cases.

Colorectal Cancer Treatment
Leukemia Therapies
Advanced Renal Cancer

Research includes evaluation of targeted therapies and immunotherapy approaches.

02 Neurological Disorders

Comprehensive studies addressing Parkinson's disease, Frontotemporal Dementia, and Alzheimer's-related psychosis. Research focuses on novel therapeutic approaches and disease-modifying treatments.

Early-Stage Parkinson's Treatment
Dementia Management
Neurological Drug Development

Trials aim to improve patient outcomes and quality of life.

03 Autoimmune Conditions

Groundbreaking research in Psoriatic Arthritis, Crohn's Disease, and Sjögren's Syndrome. Studies evaluate biological therapies and innovative treatment approaches.

Inflammatory Disease Management
Autoimmune Response Modulation
Novel Therapeutic Approaches

Focus on developing targeted treatments for chronic conditions.

04 Cardiovascular Research

Studies addressing heart failure prevention and cardiovascular disease. Research evaluates new combination therapies and preventive approaches.

Heart Failure Prevention
Cardiovascular Risk Reduction
Therapeutic Combinations

Emphasis on preventive strategies and innovative treatments.

Back to Italy All countries